-
Recent Posts
Topics
- Crowdsourcing (47)
- Global Innovation (9)
- Health Care (6)
- Innovation (63)
- Innovation Service Providers (4)
- Internal Innovation Networks (6)
- Portfolio Management (4)
- Rewards and Recognition (6)
- Startups (12)
- Uncategorized (12)
Archives
- September 2019
- April 2019
- March 2019
- January 2019
- November 2018
- July 2018
- June 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- January 2015
- December 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
Social
Follow me on Twitter
My Tweets- Follow on WordPress.com
Tag Archives: Clayton Christensen
Dis-r-r-r-uption!
My previous post has triggered a number of interesting, often negative, comments in various LinkedIn Groups. My opponents criticized my suggestion that the current state of innovation wasn’t as bad (“broken”) as a few recent articles I referred to were … Continue reading
Should We Celebrate Failure Worth A Billion?
As every popular topic, innovation is a powerful magnet for clichés. Some of them obliterate more than illuminate. For example, I’m not sure that mixing innovation with DNA is a good idea. Though I kind of understand what Clayton Christensen … Continue reading
Posted in Portfolio Management
Tagged cancer, Clayton Christensen, Clinical Trials, Drug Development, FDA, Innovation, Phase III, The innovator’s DNA
8 Comments
